OMX Copenhagen Index Sees Significant Surge

The OMX Copenhagen 20 index experienced a remarkable surge of over 6% this Thursday, a movement largely fueled by a dramatic rebound in Novo Nordisk shares. This uptick came in the wake of less-than-stellar results from its competitor, Eli Lilly.

Novo Nordisk's Stock Climbs

Following the disappointing outcomes of Eli Lilly's weight-loss drug trial, which led to a 12.9% drop in Lilly's shares, Novo Nordisk's stock witnessed a significant increase. The pharmaceutical giant reported that patients undergoing treatment with orforglipron lost an average of 12.4% of their body weight, figures that fell at the lower spectrum of market expectations for this highly anticipated medication.

Market Reaction

By 1:20 pm CET, Novo Nordisk's shares had soared more than 12%, reaching 324 Danish kroner, marking a pivotal moment in the day's trading activities.